<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/neubase-therapeutics-nasdaqnbse-lowered-to-sell-at-valuengine.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T12:00:41+00:00"/>
    <meta property="og:title" content="NeuBase Therapeutics (NASDAQ:NBSE) Lowered to Sell at ValuEngine"/>
    <meta property="og:description" content="ValuEngine lowered shares of NeuBase Therapeutics (NASDAQ:NBSE) from a hold rating to a sell rating in a report published on Wednesday morning, ValuEngine reports. NBSE has been the subject of several other research reports. HC Wainwright assumed coverage on NeuBase Therapeutics in a report on Tuesday, October 29th. They issued a buy rating and a […]"/>
  </head>
  <body>
    <article>
      <h1>NeuBase Therapeutics (NASDAQ:NBSE) Lowered to Sell at ValuEngine</h1>
      <address><time datetime="2019-11-24T12:00:41+00:00">24 Nov 2019, 12:00</time> by <a rel="author" href="https://www.thecerbatgem.com/author/jessica" target="_blank">Jessica Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p><a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=NBSE">ValuEngine</a> lowered shares of NeuBase Therapeutics (NASDAQ:NBSE) from a hold rating to a sell rating in a report published on Wednesday morning, <a href="https://www.valuengine.com/">ValuEngine</a> reports.</p>
      <p>NBSE has been the subject of several other research reports. HC Wainwright assumed coverage on NeuBase Therapeutics in a report on Tuesday, October 29th. They issued a buy rating and a $14.00 price target for the company. Oppenheimer assumed coverage on NeuBase Therapeutics in a report on Wednesday. They issued an outperform rating and a $14.00 price target for the company. Finally, BTIG Research assumed coverage on NeuBase Therapeutics in a report on Tuesday, September 24th. They issued a buy rating and a $15.00 price target for the company.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/NBSE/price-target/">NASDAQ NBSE</a> traded up $0.42 during mid-day trading on Wednesday, hitting $6.43. 97,800 shares of the company were exchanged, compared to its average volume of 119,527. The business’s 50 day moving average is $4.99. NeuBase Therapeutics has a 1-year low of $1.60 and a 1-year high of $6.95.</p>
      <p>An institutional investor recently bought a new position in NeuBase Therapeutics stock. Heritage Wealth Advisors purchased a new stake in NeuBase Therapeutics (NASDAQ:NBSE) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 11,000 shares of the company’s stock, valued at approximately $54,000. Heritage Wealth Advisors owned 0.06% of NeuBase Therapeutics at the end of the most recent reporting period. 1.81% of the stock is owned by hedge funds and other institutional investors.</p>
      <p>
        <b>About NeuBase Therapeutics</b>
      </p>
      <p>NeuBase Therapeutics, Inc, a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders.</p>
      <p>Featured Story: <a href="https://www.marketbeat.com/financial-terms/what-member-countries-make-up-the-g-20/">What is the role of the G-20?</a></p>
      <p>To view ValuEngine’s full report, visit <a href="https://www.valuengine.com/rep/order_report?pid=64&amp;srchfor=NBSE">ValuEngine’s official website</a>.</p>
    </article>
  </body>
</html>